Keytruda

Male and female superheroes posing in fluttering cloaks

ESMO: Cancer vaccine and Keytruda deliver in phase 2 trial

IO Biotech's cancer vaccine, in combination with Keytruda, delivered an objective response rate of 44.4%, hitting the study's primary endpoint.

Darren Incorvaia Sep 14, 2024 2:30am

long shot miss basketball hoop fail shoot

Merck stops phase 3 TIGIT trial in lung cancer for futility

Aug 8, 2024 7:49am

step up climb ladder sky hang on rung

Immutep regains pep as cancer subgroup data show path forward

Jul 12, 2024 9:35am

boxing punch blow hit punching bag fight

Roche stops pivotal TIGIT trial as Keytruda lands knockout blow

Jul 4, 2024 5:10am

winnter trophy star

Merck's 3-pronged cancer plan stars Moderna-partnered vaccine

Jun 3, 2024 8:00am

success failure signposts

Calliditas' cancer trial misses primary goal, hits on survival

May 7, 2024 6:39am